NCT07701343Recruiting
tACS for Working Memory in Schizophrenia
Efficacy and Mechanisms of Transcranial Alternating Current Stimulation in Improving Working Memory in Patients With Schizophrenia
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
This study is a randomized, single-blind, sham-controlled crossover trial enrolling 30 schizophrenia patients, each receiving one active and one sham tACS session (7-day washout), targeting P3/P4 at individual alpha frequency (2mA, 30min) during a working memory task, with accuracy and reaction time as primary outcomes, alongside EEG and neurophysiological measures, to test the efficacy and mechanisms of individualized alpha-tACS on working memory.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 2 Jul 2026
- Start date
- Oct 2026
- Primary completion date
- Oct 2026
- Lead sponsor
- Central South University
- Diseases
- Schizophrenia
- NCT number
- NCT07701343
What you commit to
- Study type: Interventional
- Planned participants: 30
- From Oct 2026 to the primary completion date, Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously diagnosed with or comorbid any other DSM-5 mental disorder besides schizophrenia.
- Received other forms of electrical or magnetic stimulation therapy within 1 month prior to enrollment.
Other illness
- Presence of significant mood symptoms or substance use disorder (other than caffeine and/or tobacco).
- History or current presence of any major physical illness, neurological disorder, or traumatic brain injury that may affect brain structure or function.
Other
- Presence of any contraindication to transcranial alternating current stimulation (tACS).
- Pregnant or breastfeeding women, or women planning to become pregnant during the study period.
Who the study is looking for
- Aged 18-50 years, meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria for schizophrenia, confirmed by the Structured Clinical Interview for DSM-5 (SCID-5).
- Spatial span T-score \<40 on the MATRICS Consensus Cognitive Battery (MCCB).
- Taking 1-2 antipsychotic medications, with stable dosage for at least 1 week prior to enrollment. No use of mood stabilizers, antidepressants, or excessive benzodiazepines (lorazepam equivalent \>2 mg/day). The type and dosage of antipsychotic medications remain unchanged during the treatment period.
- Impaired functioning in daily activities.
- Willing to participate in this study and provide written informed consent.
Age in the registry: 18 years to 50 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Second Xiangya Hospital of Central South University Coordinator of this site? Confirm its status | Changsha | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.